This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Sofinnova Partners, a European venture capital firm, said Monday it raised 650 million euros, or $750 million, for a new fund that will support up-and-coming life sciences companies. Most of the cash will be directed toward biotechnology startups developing new drugs, while 20% to 30% of it going toward medical device makers, said Maina Bhaman, one of the firm’ ...